中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察

李慧丽 卢雪峰 李娜

李慧丽, 卢雪峰, 李娜. 恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察[J]. 临床肝胆病杂志, 2016, 32(2): 292-295. DOI: 10.3969/j.issn.1001-5256.2016.02.019.
引用本文: 李慧丽, 卢雪峰, 李娜. 恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察[J]. 临床肝胆病杂志, 2016, 32(2): 292-295. DOI: 10.3969/j.issn.1001-5256.2016.02.019.
Li HuiLi, Lu XueFeng, Li Na. Efficacy of entecavir combined with alprostadil in treatment of hepatitis B-related cirrhotic ascites[J]. J Clin Hepatol, 2016, 32(2): 292-295. DOI: 10.3969/j.issn.1001-5256.2016.02.019.
Citation: Li HuiLi, Lu XueFeng, Li Na. Efficacy of entecavir combined with alprostadil in treatment of hepatitis B-related cirrhotic ascites[J]. J Clin Hepatol, 2016, 32(2): 292-295. DOI: 10.3969/j.issn.1001-5256.2016.02.019.

恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.02.019
详细信息
  • 中图分类号: R575.2;R512.62

Efficacy of entecavir combined with alprostadil in treatment of hepatitis B-related cirrhotic ascites

  • 摘要: 目的观察恩替卡韦与前列地尔联合治疗乙型肝炎肝硬化腹水的临床疗效。方法选取2012年5月-2014年2月德州市中医院收治的乙型肝炎肝硬化腹水患者100例,随机分为治疗组与对照组,每组各50例,两组均常规给予保肝、利尿、间断补充白蛋白(Alb)治疗,其中治疗组加用恩替卡韦0.5 mg口服,1次/d,联合前列地尔20μg+5%葡萄糖注射液100 ml静滴,1次/d,观察组只加用恩替卡韦0.5 mg口服,1次/d。住院治疗4周,观察两组治疗前后腹水消退情况、ALT、TBil、Alb、血液尿素氮(BUN)、肌酐(Cr)、凝血酶原活动度(PTA)、HBV DNA水平变化。出院后两组患者继续口服恩替卡韦0.5 mg,1次/d,随访3个月观察远期疗效。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果两组患者治疗后腹水量较治疗前均有不同程度降低,治疗组总有效率(84%)高于对照组(64%),差异有统计学意义(χ2=6.018,P<0.05);两组患者肝肾功能各项指标(ALT、TBil、Alb、BUN、Cr)及PTA治疗后较治疗前均有不同程度改善,且治疗组疗效优于对照组,两组治疗后各项...

     

  • [1]YU JP.Effect of antiviral therapy for patients with decompensated hepatitis B cirrhosis[J].Chin Hepatol,2013,18(2):132-133.(in Chinese)余佳平.乙型肝炎肝硬化失代偿期患者抗病毒治疗的疗效观察[J].肝脏,2013,18(2):132-133.
    [2]WANG Y,QIN CZ,SHAO JL.Clinical diagnosis and treatment of liver cirrhosis with refractory ascites:an analysis of 50 cases[J].Chin Foreign Med Res,2013,11(32):18-19.(in Chinese)王毅,秦长忠,邵佳亮.50例肝硬化合并难治性肝腹水的临床诊治分析[J].中外医学研究,2013,11(32):18-19.
    [3] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline for prevention and treatment of chronic hepatitis B[J].J Clin Hepatol,2006,22(1):3-15.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志,2006,22(1):3-15.
    [4] Branch of Gastrointestinal Diseases,China Association of Chinese Medicine.Expert consensus on standardized TCM diagnosis and treatment of cirrhotic ascites(2011,Hainan)[J].Chin J Integr Tradit West Med,2012,32(12):1693-1696.(in Chinese)中华中医药学会脾胃病分会.肝硬化腹水中医诊疗规范专家共识意见(2011年,海南)[J].中国中西医结合杂志,2012,32(12):1693-1696.
    [5]TANG SL,LIANG XM,ZHANG GY.Advances in pharmacological action and clinical application of alprostadil injection[J].China Pharm,2012,23(25):2383-2385.(in Chinese)汤晟凌,梁晓美,张国勇.前列地尔注射液的药理作用与临床应用进展[J].中国药房,2012,23(25):2383-2385.
    [6]WEI AL,GUAN ZJ,LONG FL,et al.Advances in the treatment of chronic severe hepatitis of traditional Chinese and western medicine[J].J Liaoning Univ Tradit Chin Med,2012,14(12):7-9.(in Chinese)伟艾凌,官志杰,龙富立,等.慢性重型肝炎中西医治疗进展[J].辽宁中医药大学学报,2012,14(12):7-9.
    [7]ZHANG XF.Treatment of severe hepatitis with hepatorenal syndrome:an analysis of 66 cases[J].Shaanxi Med J,2013,42(7):844-845.(in Chinese)张向飞.重型肝炎合并肝肾综合征66例治疗观察[J].陕西医学杂志,2013,42(7):844-845.
    [8]NI XL,GU DY,HU GH.Effects of alprostadil in the prevention of portal vein thrombosis after splenectomy and devascularization:a historical control study[J].Chin J Hepatobiliary Surg,2014,20(5):351-354.(in Chinese)倪晓凌,顾大镛,胡国华.前列地尔预防脾切除和断流术后门静脉系统血栓形成的历史对照研究[J].中华肝胆外科杂志,2014,20(5):351-354.
    [9]FANG W,LI H,ZHOU L,et al.Effect of prostaglandin E1 on TNF-induced vascular inflammation in human umbilical vein endothelial cells[J].Can J Physiol Pharmacol,2010,88(5):576-583.
    [10]ZHANG KQ,LI YY,XIAO YQ,et al.Significance of detection of HBV DNA in liver tissue of serum HBV DNA negative hepatitis B cirrhosis patients[J].World Chin J Dig,2014,22(20):2937-2941.(in Chinese)张克勤,李娅娅,肖影群,等.检测血清HBV DNA阴性的乙型肝炎肝硬化患者肝内HBV DNA的意义[J].世界华人消化杂志,2014,22(20):2937-2941.
    [11]CHUNG WG,KIM HJ,CHOE YG,et al.Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-nave patients with chronic hepatitis B infection[J].Clin Mol Hepatol,2012,18(2):195-202.
  • 加载中
计量
  • 文章访问数:  2198
  • HTML全文浏览量:  10
  • PDF下载量:  422
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-07-31
  • 出版日期:  2016-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回